0001479290-19-000010.txt : 20190123
0001479290-19-000010.hdr.sgml : 20190123
20190123213809
ACCESSION NUMBER: 0001479290-19-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190122
FILED AS OF DATE: 20190123
DATE AS OF CHANGE: 20190123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Allouche Cyril
CENTRAL INDEX KEY: 0001744573
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 19538533
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
wf-form4_154829747297041.xml
FORM 4
X0306
4
2019-01-22
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001744573
Allouche Cyril
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BLVD
NEWARK
CA
94560
0
1
0
0
Principal Accounting Officer
Common Stock
2019-01-22
4
M
0
625
13.35
A
4625
D
Common Stock
2019-01-22
4
S
0
625
17.77
D
4000
D
Employee Stock Option (Right to Buy)
13.35
2019-01-22
4
M
0
625
0
D
2026-10-30
Common Stock
625.0
6875
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche.
The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
/s/ Gordon Ho, Attorney-in-Fact
2019-01-23